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Abstract
Introduction Increased levels of proinflammatory cyto-
kines seem to play a pivotal role in the development of
back pain in a subpopulation of patients with degenera-
tive intervertebral disc (IVD) disease. As current treat-
ment options are mostly limited to surgical interventions
or conservative treatment, anti-inflammatory substances
might offer a novel, more target-orientated therapeutic
approach. Triptolide (TPL), a natural substance found in
the Chinese medicinal herb Tripterygium wilfordii Hook,
has been demonstrated to possess anti-inflammatory
effects in various cells, but no studies exist so far for the
IVD. Therefore, the aim of this study was to determine
the effects of TPL on human IVD cells by analyzing
changes in gene expression and underlying molecular
mechanisms.
Materials and methods In order to investigate the anti-
inflammatory, anabolic and anti-catabolic effect of TPL,
dose-dependency experiments (n = 5) and time course
experiments (n = 5) were performed on IL-1b presti-
mulated human IVD cells and changes in gene expres-
sion of IL-6/-8, TNF-a, PGE2S, MMP1/2/3/13, aggrecan
and collagen-I/-II were analyzed by real-time RT-PCR.
The molecular mechanisms underlying the effects
observed upon TPL treatment were investigated by
analyzing involvement of Toll-like receptors TLR2/4
(real-time RT-PCR, n = 5), NF-jB, MAP kinases p38,
ERK and JNK (immunoblotting and immunocytochem-
istry, n = 4) as well as RNA polymerase II (immuno-
blotting, n = 3).
Results Results showed that 50 nM TPL exhibited an
anti-inflammatory, anti-catabolic and anabolic effect on
the mRNA level for IL-6/-8, PGE2S, MMP1/2/3/13,
aggrecan, collagen-II and TLR2/4, with most pronounced
changes after 18 h for proinflammatory cytokines and
MMPs or 30 h for TLRs and matrix proteins. However,
we also observed an up-regulation of TNF-a at higher
concentrations. The effects of TPL did not seem to be
mediated via an inhibition of NF-jB or a decrease of
RNA polymerase II levels, but TPL influenced activity
of MAP kinases p38 and ERK (but not JNK) and
expression of TLR2/4.
Conclusions In conclusion, TPL may possess promising
potential for the treatment of inflammation-related disco-
genic back pain in vitro, but its analgetic effect will need to
be confirmed in an appropriate in vivo animal model.
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Introduction
Tripterygium wilfordii Hook F, a vine native to several
Asian countries, has been widely used in the traditional
Chinese medicine. Triptolide (TPL), a diterpenoid triep-
oxide, was identified as its major active component. It has
been demonstrated to possess strong immunosuppressive
and anti-inflammatory effects [1, 2]. TPL has been used in
treating inflammatory joint diseases [3, 4], but could
potentially also be applied in other inflammation-related
diseases. As TPL has been additionally shown to possess
anti-proliferative and pro-apoptotic activity in various
types of cancer cells, it is considered a possible new can-
didate in the group of new cancer therapeutics [5].
Current literature on the intervertebral disc (IVD) pro-
vides clear evidence for the relevance of inflammatory
mediators in the development of back pain. Nucleus pul-
posus (NP) tissue has long been known to induce radicu-
lopathic pain, due to chemical irritation of dorsal root
ganglion nerves induced by proinflammatory cytokines
present in this tissue [6–10]. Similarly, degenerative disc
disease (leading to so-called discogenic back pain) seems
to correlate with increased levels of proinflammatory
cytokines such as interleukin 1b (IL-1b), interleukin 6 (IL-6),
interleukin 8 (IL-8) and tumor necrosis factor a (TNF-a)
[11–15]. Although basic knowledge on the increased
expression of inflammatory mediators in certain cases of
back pain (i.e. discogenic back pain, NP mediated back
pain) exists, the molecular mechanisms underlying these
processes are not yet elucidated. However, molecular bio-
logical research of the past decades indicates that the MAP
kinase pathways as well as the transcription factor nuclear
factor-jB (NF-jB) are the major mechanisms regulating
inflammatory responses in vivo and in vitro. Additionally,
TPL has been described to not only influence NF-jB [16–
20] and MAP kinases [17, 18, 21], but also to reduce levels
of RNA polymerase II (=enzyme that is essential in the
process of transcription) in cancer cells [5], thus possibly
explaining the broad spectrum of genes whose expression
is influenced upon TPL treatment.
In order to suppress inflammation, corticosteroidal
substances are frequently used, which are, however, known
to have a significant risk for side effects. There is thus
increased interest in alternative substances that possess a
strong anti-inflammatory and anti-catabolic potential. In
the present study, we examined the effects of TPL on the
inflammatory and catabolic response of human IVD cells
that were prestimulated with recombinant IL-1b to simu-
late an inflammatory situation. We also analyzed the
molecular mechanisms mediating the inhibition of cytokine
expression by investigating the role of the transcription
factor nuclear factor kappa B (NF-jB), the Toll-like
receptors TLR2 and TLR4, the mitogen-activated protein
(MAP) kinases including p38, ERK (=extracellular signal-
regulated kinase) and JNK (=c-Jun N-terminal kinase) as
well as the involvement of RNA polymerase II.
Materials and methods
Materials
Materials used in this study are specified in Table 1.
Human intervertebral disc cell culture
Human IVD tissue was removed from patients undergoing
spinal surgery for discectomy or interbody fusion for
degenerative disc disease or disc herniation (for detailed
information see Table 2) after obtaining informed consent
in accordance with the local ethical guidelines.
Table 1 Detailed information about materials used in this study
Material Supplier
Ampicillin Gibco
BSA Sigma-Aldrich
Bradford reagent Bio-Rad
Collagenase NB4 Serva
Dispase II Roche
DMSO Sigma
ERK/p-ERK antibodies Cell Signaling
F-12/DMEM medium Sigma-Aldrich
Fetal calf serum (FCS) Tecomedical
HRP-mouse antibody Amersham
HRP-rabbit antibody Sigma
Hyperfilm ECL Amersham
Hybond-P PVDF Amersham
IL-1b recombinant Peprotech
JNK/p-JNK antibodies Cell Signaling
MTT Sigma-Aldrich
p38/p-p38 antibodies Cell Signaling
p65 antibody Santa Cruz
PARP1 antibody Santa Cruz
PCR Master Mix Applied Biosystems
Penicillin Gibco
PureLink RNA Kit Invitrogen
Reverse transcription reagents Applied Biosystems
RNA polymerase II antibody Santa Cruz
Streptomycin Gibco
SuperSignal West Dura Socochim
Triptolide Sigma
Trypsin Invitrogen
Tubulin antibody Cell Signaling
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IVD tissue was enzymatically digested (0.2% collage-
nase NB4, 0.3% dispase II) for 4–8 h and cells were
thereafter cultured in DMEM/F12 supplemented with 10%
FCS, penicillin (50 units/ml), streptomycin (50 lg/ml) and
ampicillin (125 ng/ml) up to passage 2–3.
Viability measurement
Cellular viability after treatment with different concentra-
tions of TPL (6, 18 and 30 h) was analyzed using the MTT
assay as previously described, which has also been shown
to be comparable to other viability/toxicity measurements
(Picogreen assay, cell counting) [22]. Non-toxic concen-
trations were chosen for subsequent experiments.
Gene expression analysis
In order to investigate the effects of TPL on the expression
of inflammatory mediators (IL-6, IL-8, TNF-a, PGE2S =
prostaglandin E2 synthase), matrix degrading enzymes
(MMP1, MMP2, MMP3, MMP13), Toll-like receptors
(TLR2, TLR4) and anabolic genes (aggrecan collagen-I,
collagen-II), dose-dependency (0.5, 5, 50 nM—all 18 h)
and time course experiments (6, 18, 30 h—all 50 nM) were
performed. Cells were serum starved for 2 h and then
exposed to 5 ng/ml IL-1b for 2 h before treating cells with
different concentration of TPL for 18 h. The most active
concentration was chosen for further time course experi-
ments. Untreated control cells as well as DMSO treated cells
(=solvent) were included in each experiment. After treat-
ment, cells were harvested by trypsin, RNA was isolated,
reverse transcribed and gene expression was measured on
the StepOne Plus PCR machine (Applied Biosystems) using
real-time RT-PCR as previously described. Briefly, human
specific probes and primers (see Table 3), TaqMan real-time
RT-PCR Mix and cDNA were mixed, measured in dupli-
cates and data was analyzed by using the comparative ct
method (2DDCt method, housekeeping gene = Tata Box
binding protein = TBP). The assay was performed on
samples from five independent experiments.
Table 2 Demographic data on
surgical disc samples used in
this study
M male, F female, grade
classification of intervertebral
disc degeneration by Pfirrmann
grade
Number Age Sex Pathology Grade Level
1 60 M Disc herniation 3 L4/5
2 51 F Sympt. disc disease 4 L5/S1
3 42 F Disc herniation 4 L4/5
4 50 M Disc herniation 4 L4/5
5 47 M Disc herniation 4 L4/5
6 46 F Disc herniation 3 L5/S1
7 54 M Disc herniation 4 L4/5
8 27 F Disc herniation 3 L4/5
9 26 F Disc herniation 3 L4/5
10 43 M Disc herniation 4 L4/5
11 43 F Disc herniation 4 L4/5
12 50 F Disc herniation 3 L5/S1
13 49 M Disc herniation 4 L5/S1
14 26 M Disc herniation 4 L5/S1
15 45 F Disc herniation 4 L5/S1
16 40 F Disc herniation 4 L4/5
17 57 M Disc herniation 4 L4/5
18 44 F Disc herniation 3 L5/S1
19 60 M Disc herniation 4 L4/5
20 47 M Disc herniation 4 L4/5
21 36 M Disc herniation 3 C5/6
22 53 M Disc herniation 4 L4/5
23 48 F Disc herniation 4 L4/5
24 48 F Disc herniation 3 L4/5
25 42 F Disc herniation 4 L4/5
26 60 M Sympt. disc disease 3 L4/5
27 46 F Disc herniation 4 L5/S1
28 27 F Disc herniation 4 L4/5
29 42 M Disc herniation 3 L4/5
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Pathway analysis (NF-jB, MAP kinases)
In order to investigate potentially involved pathways,
immunoblotting was performed for p65 (subunit of NF-jB)
as well as for the phosphorylated (=activated) and unphos-
phorylated MAP kinases p38, ERK and JNK. Briefly, cells
were stimulated with IL-1b or co-stimulated with IL-1b and
50 nM of TPL (the most potent concentration in gene
expression experiments) for 15 min (MAP kinases) or
60 min (NF-jB). Unstimulated control cells were included
as well.
For NF-jB immunoblotting, nuclear extracts were
prepared according to standard protocols, protein content
was measured by Bradford assay, nuclear extracts were
fractioned by SDS-PAGE, proteins were transferred onto
membranes and first incubated with a p65 antibody and
then with the appropriate secondary HRP-labeled anti-
body before analyzing chemiluminescence. In order to
confirm NF-jB immunoblotting results, nuclear trans-
location of p65 was additionally examined by immu-
nocytochemistry in methanol-fixed cells using standard
techniques.
For MAP kinase immunoblotting, whole cell extracts
were prepared as previously described, protein content
was measured by Bradford assay, whole cell extracts
were fractioned by SDS-PAGE, proteins were transferred
onto membranes and first incubated with antibodies rec-
ognizing phosphorylated or unphosphorylated p38, ERK
(=p42/44) or JNK antibody and then with the appropriate
secondary HRP-labeled antibody before analyzing chemilu-
minescence.
PARP1 and tubulin were used as loading controls for
p65 and MAP kinase immunoblotting, respectively. Each
assay was performed on samples from four independent
experiments.
Analysis of RNA polymerase II protein expression
level
The effect of TPL on RNA polymerase II expression was
investigated by immunoblotting of whole cell extracts that
were obtained from cells stimulated with either IL-1b alone
or IL-1b prestimulated cells with 50 nM of TPL for 6, 18
or 30 h (see ‘‘Gene expression analysis’’), using a specific
antibody recognizing human RNA polymerase II. Tubulin
was used as a loading control and the assay was performed
on samples from three independent experiments.
Statistical analysis
Statistical analysis was performed by Mann–Whitney
U Test (two-tailed) using the SPSS software. A signifi-
cance level of P \ 0.05 was considered statistically
significant.
Results
Viability
TPL exhibited a cytotoxic effect at concentrations of
250 nM and higher already within 18 h (data not shown).
For further experiments, non-toxic concentrations of 0.5, 5
and 50 nM were chosen, which did not exhibit any statis-
tically significant cytotoxic effect within the time frame of
the subsequent experiments (up to 30 h).
Gene expression
Confirming our data from previous studies, pre-treatment
with IL-1b stimulated expression of IL-6, IL-8, TNF-a,
Table 3 Primers/probes used
for real-time RT-PCR
(TaqMan Gene Expression
Assays, Applied Biosystems)
Gene Primer sequence number Base pairs
Aggrecan Hs00202971_m1 93
Collagen-I Hs00164004_m1 66
Collagen-II Hs00264051_m1 124
Interleukin-6 (IL-6) Hs00174131_m1 95
Interleukin-8 (IL-8) Hs00174103_m1 101
Matrixmetalloproteinase-1 (MMP1) Hs00233958_m1 133
Matrixmetalloproteinase-2 (MMP2) Hs00174131_m1 96
Matrixmetalloproteinase-3 (MMP3) Hs01548724_m1 98
Matrixmetalloproteinase-13 (MMP13) Hs00233992_m1 91
Prostaglandin E2 Synthase (PGE2S) Hs00228159_m1 66
Tata Box binding protein (TBP) Hs00427620_m1 91
Toll-like receptor 2 (TLR2) Hs00152932_m1 80
Toll-like receptor 4 (TLR4) Hs00152939_m1 89
Tumor necrosis factor a (TNF-a) Hs00174128_m1 80
Eur Spine J (2012) 21 (Suppl 6):S850–S859 S853
123
MMP1, MMP2, MMP3, MMP13 as well as TLR2 and
reduced expression of aggrecan, collagen-I and collagen-II
(for detailed results, see Table 4), but did not influence
expression of PGE2S and TLR4.
In the first set of experiments, IL-1b prestimulated cells
were treated with different concentrations of TPL (0.5, 5,
50 nM) for 18 h. We observed a dose-dependent inhibition
of the expression of inflammatory mediators (IL-6, IL-8,
PGE2S), matrix degrading enzymes (MMP1, MMP2,
MMP3, MMP13) and Toll-like receptors (TLR2, TLR4).
For aggrecan, a 1.9-fold increase was observed with 50 nM
after 18 h, while no changes occurred with the lower
concentrations. Collagen-I and collagen-II were either not
altered or slightly decreased after 18 h. For all results,
see Fig. 1a–d. TNF-a expression was increased at
concentrations of 5 nM (2.8-fold) and 50 nM (21.2-fold)
(data not shown).
For the second set of experiments, IL-1b prestimulated
cells were treated with 50 nM TPL for 6, 18 or 30 h (time
course experiments). Results show that TPL exhibits its
anti-inflammatory, anti-catabolic and anabolic effects
already after 6 h with regard to IL-6, IL-8, MMP1, MMP3,
MMP13, aggrecan and TLR2, but its effects were more
pronounced after longer incubation periods (18 and 30 h),
including an increase of collagen-II (Fig. 2a–d). The most
distinct reduction in gene expression was observed at 18 h
for IL-6 (100 ? 4.1%), MMP1 (100 ? 11.1%), MMP3
(100 ? 15.7%), MMP13 (100 ? 13.3%) and TLR4 (100 ?
18.2%), but effects were also significant for IL-8 (100 ?
36.5%), MMP2 (100 ? 42.2%), PGE2S (100 ? 26.4%)
Table 4 Effects of IL-1b
stimulation on mRNA levels of
candidate genes after 6, 18 and
30 h, indicated as fold change
relative to no treatment (mean,
SEM, P values)
Data was obtained by real-time
RT-PCR (2DDCt method)
(n = 5). PGE2S and TLR4 were
not significantly regulated by
IL-1b stimulation (values not
shown)
Gene Time point (h) Mean fold change SEM P value
Aggrecan 6 -1.4 0.3 0.001
18 -1.8 0.5 0.001
30 -2.7 0.5 \0.0001
Collagen-I 6 -1.0 0.2 0.001
18 -1.3 0.5 0.015
30 -2.1 0.2 \0.0001
Collagen-II 6 -2.1 0.2 \0.0001
18 -8.9 3.2 \0.0001
30 -7.2 1.1 \0.0001
IL-6 6 432.7 74.3 \0.0001
18 6236.1 2601.3 \0.0001
30 7350.5 2557.3 \0.0001
IL-8 6 558.4 175.2 \0.0001
18 1102.5 291.3 \0.0001
30 1983.8 649.3 \0.0001
MMP1 6 449.1 163.9 \0.0001
18 1576.5 470.9 \0.001
30 2032.6 631.9 \0.0001
MMP2 6 0.7 0.3 0.419
18 2.1 0.5 \0.0001
30 3.4 0.3 \0.0001
MMP3 6 327.7 124.9 \0.0001
18 1143.5 240.7 \0.0001
30 1768.8 636.0 \0.0001
MMP13 6 79.1 20.6 \0.0001
18 114.6 30.2 \0.0001
30 297.3 140.0 \0.0001
TNF-a 6 78.5 16.4 \0.0001
18 41.1 14.4 \0.0001
30 46.0 11.3 \0.0001
TLR2 6 16.5 1.9 \0.0001
18 13.5 1.2 \0.0001
30 13.4 2.1 \0.0001
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and TLR2 (100 ? 30.1%). We observed a time-dependent
up-regulation of aggrecan with a significantly increase after
18 h (1.8-fold), but the effect was more pronounced after
30 h (2.7-fold). Similarly, collagen-II expression was sig-
nificantly induced after 30 h (3.1-fold), while collagen-I
expression was not altered at any time point. While matrix
proteins were most regulated after 30 h, effects declined
for several genes at this time point already. Nevertheless,
the inhibitory effect remained significant for IL-6, MMP1,
MMP2, MMP13, PGE2S, TLR2 and TLR4 (Fig. 2a–d). In
accordance with results of the dose-dependency experi-
ments, TNF-a expression was up-regulated, especially after
30 h (6 h: 4.8-fold; 18 h: 101.0-fold; 30 h: 987.3-fold)
(data not shown).
NF-jB and MAP kinase pathway
Immunoblotting for p65 indicates that IL-1b prestimulation
caused nuclear translocation of p65, which is the first step
of NF-jB activation. However, treating IL-1b prestimu-
lated cells with 50 nM TPL was not able to prevent or
reverse nuclear translocation of NF-jB. Figure 3a shows
that the p65 band of TPL treated samples is not reduced
compared to IL-1b stimulated samples, while untreated
cells show a much smaller amount of target protein as
detected by immunoblotting of nuclear extracts. Equal
protein loading was confirmed by PARP1 detection. This
pattern could be confirmed by immunocytochemistry as
shown in Fig. 3b.
Immunoblotting for MAP kinases indicated that IL-1b
prestimulation caused phosphorylation of p38, ERK and
JNK, which is indicative of their activation. TPL treat-
ment (50 nM) strongly reduced levels of phosphorylated
p38 (Fig. 3c) and slightly reduced levels of phospory-
lated ERK (Fig. 3d), but not of JNK (Fig. 3e) compared
to IL-1b stimulated samples. As expected, levels of un-
phosporylated p38, ERK and JNK were similar in all
groups. Equal protein loading was confirmed by tubulin
detection.
RNA polymerase II protein expression level
Immunoblotting for RNA polymerase II indicates that
50 nM TPL did not influence its expression levels at any
investigated time point (6, 18, 30 h), compared to IL-1b
stimulated samples or untreated samples (Fig. 4).
dc
a b
Fig. 1 Effects of different concentrations of TPL (0.5, 5, 50 nM—
18 h) on mRNA levels of candidate genes, indicated as fold change
relative to IL-1b-prestimulation (set to 100%): a inflammatory
mediators (IL-6, IL-8, PGE2S), b matrix degrading enzymes
(MMP1, MMP2, MMP3, MMP13), c matrix proteins (aggrecan,
collagen-I, collagen-II) and d Toll-like receptors (TLR2, TLR4). Data
was obtained by real-time RT-PCR (2DDCt method) and is presented
as Mean and SEM (n = 5). Asterisks indicate statistical significance
(P \ 0.05); an asterisk in brackets indicates barely significant (IL-8:
P = 0.051)
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Fig. 2 Effects of TPL (50 nM) on mRNA levels of candidate genes
after different time points (6, 18, 30 h), indicated as fold change
relative to IL-1b-prestimulation (set to 100%): a Inflammatory
mediators (IL-6, IL-8, PGE2S), b matrix degrading enzymes
(MMP1, MMP2, MMP3, MMP13), c matrix proteins (aggrecan,
collagen-I, collagen-II) and d Toll-like receptors (TLR2, TLR4). Data
was obtained by real-time RT-PCR (2DDCt method) and is presented
as Mean and SEM (n = 6). Asterisks indicate statistical significance
(P \ 0.05)
Fig. 3 Effects of TPL (50 nM) on the induction/activity of NF-jB
and MAP kinases, detected by immunoblotting (IB) and immunocy-
tochemistry (IC). NF-jB induction was detected by a IB of nuclear
extracts (n = 4, 60 min) and b IC (n = 4, 60 min). MAP kinase
activity was detected by IB of whole cell extracts (n = 4, 15 min) for
c p38, d ERK and e JNK. One representative sample is shown. For IB,
PARP1 or tubulin was used as a loading control. For IC, Hoechst
counterstaining of cell nuclei was performed
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Discussion
Tripterygium wilfordii Hook has its therapeutic origin in
the traditional Chinese medicine (TCM), which—during
the past years—has been recognized by researchers world-
wide as an important and extensive source for revealing
novel lead molecules for modern drug discovery. However,
typical TCM preparations usually combine multiple herbs
(or other natural substances) with the respective variability
in composition (e.g. due to harvesting periods) and can thus
not be regarded as standardized products. In order to create
patentable and marketable products for conventional
Western medicine, the active component has to be identi-
fied and its molecular mechanism of action should be
elucidated. TPL has been identified as one of the major
bioactive components of Tripterygium wilfordii Hook. The
therapeutic potential of TPL or Tripterygium wilfordii
Hook is currently investigated at the stage of clinical trials
for the treatment of polycystic kidney disease, glomerulo-
sclerosis, nephropathy, spondylitis and rheumatoid arthritis
(http://clinicaltrials.gov). On a laboratory stage, the anti-
inflammatory and anti-catabolic effects of TPL are cur-
rently being investigated in even more cell and tissue types,
thus trying to broaden its therapeutic use. However, to the
authors’ knowledge, no studies have been performed with
regard to IVD diseases yet.
Results from this study on human IVD cells indicate that
TPL can effectively reduce mRNA levels of major
inflammatory mediators (IL-6, IL-8, PGES2) and matrix
degrading enzymes (MMP1, MMP2, MMP3, MMP13),
with highest effects after 18 h. However, mRNA expres-
sion of TNF-a was up-regulated upon TPL treatment.
Additionally, 50 nM TPL significantly induced levels of
relevant matrix proteins (aggrecan, collagen-II), especially
after 30 h. Why lower concentrations of TPL seemed to
inhibit collagen-II expression at earlier time points (18 h)
is currently not clear. While matrix proteins responded
strongly to TPL treatment after 30 h, effects were not as
pronounced anymore at this time point for most inflam-
matory and catabolic genes, indicating that TPL may
possess a limited bioactivity time frame. However, usage
of a slow release system may overcome this restriction.
Pathway analysis provides evidence that this effect may be
(at least partially) mediated by the MAP kinases p38 and
ERK (whose activity we saw to be influenced by TPL),
while the transcription factor NF-jB, the MAP kinase JNK
or the RNA polymerase II did not seem to be involved in
signal transduction. Additionally, expression of Toll-like
receptors TLR2 and TLR4 was reduced by TPL treatment.
The observed inhibition of mRNA for the major matrix
degrading enzymes and the induction of matrix proteins in
human IVD cells suggests that TPL can block tissue degra-
dation and may thus potentially slow down or prevent further
disc degeneration. A comparable anti-catabolic potential of
TPL has been described in other cell types before, e.g. TPL
was shown to inhibit expression of proMMPs 1 and 3 in
human synovial fibroblasts [23] and expression of MMP3,
MMP13 and ADAMTS4 in human OA chondrocytes [24].
In the present in vitro study, TPL was able to inhibit
inflammatory responses in human IVD cells, which is
similar to macrophages (inhibition of PGE2, IL-1a, IL-b
and IL-6 expression) [23] and various kinds of fibroblasts
(inhibition of PGE2, COX-2, IL-6 and IL-8 expression)
[20, 25–27]. Although to the author’s knowledge only few
studies exist to date that investigated the anti-inflammatory
in vitro effect of TPL in chondrocytes [24], its effects were
tested in a collagen-induced arthritis mouse model in vivo.
Results indicate that TPL can reduce inflammatory
responses and cartilage damage in the joint tissues by
inhibiting expression of MMP3, MMP13, PGE2, COX-2,
IL-1b, IL-6, TNF-a [16–18]. While we can confirm the
inhibition of MMP3, MMP13 and IL-6 in human IVD cells
in vitro, expression of TNF-a was induced in our system
and will thus be subject to further scrutiny in next exper-
iments. The increased level of TNF-a may not only be
critical for any in vivo application, but may have also
influenced our results if transferred to the protein level as it
may be responsible for the sustained and unaltered NF-jB
activation. Activation of NF-jB has been described to
cause an anti-apoptotic effect, thus possibly masking any
toxic effect of TPL [28]. However, in order to verify
whether this is the case, experiments with NF-jB inhibition
(e.g. using Ad5-I kappa B alpha Delta N; MG132 [28]) will
need to be performed in the future. This will be important
as in tumor cells, TPL could in contrast block TNF-a-
induced activation of NF-jB, resulting in enhanced apop-
tosis induced by TNF-a [29].
Based on the obtained results, the next step will be to
investigate the anti-inflammatory and analgetic behavior of
TPL in vivo, using a well-established rodent model of
radiculopathic pain [30]. As bioavailability and diffusion
rates in vivo are unclear, the in vitro data obtained in this
study can only provide a first basis to choose appropriate in
vivo application modes.
Fig. 4 Effects of TPL (50 nM) on the expression levels of RNA
polymerase II, detected by immunoblotting of whole cell extracts
(n = 3) (6, 18, 30 h). One representative sample is shown. Tubulin
was used as a loading control
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Based on the promising gene expression results, we
further sought to investigate the underlying molecular
mechanism. Findings in the literature indicate that the NF-
jB pathway is one of the molecular mechanisms underly-
ing the cellular responses observed after TPL treatment
[16–20]. However, the effects of TPL seem to be mediated
by a complex interplay of various signaling mechanisms,
including the MAP kinases p38 [17], ERK [21] or JNK [17,
18] as well as the transcription factor AP-1 [19]. We were
able to show that in IVD cells, TPL may work in part by
interfering with phosphorylation of the MAP kinases p38/
ERK and by regulating expression of TLR2/4, but probably
not by inhibiting NF-jB or JNK activity, although this is
described for multiple other cell types [16–20], indicating
that the involved signaling pathways are cell-specific. In
addition, we investigated whether TPL is able to influence
protein levels of RNA polymerase II as this has been
described to be a major mechanism of action of TPL in
cancer cells most recently [5]. However, in human disc
cells, TPL did not reduce RNA polymerase II levels as
shown by immunoblotting, indicating once more that TPL
acts cell-specifically on certain mechanisms/pathways.
Clinical relevance
TPL seems to be a promising candidate to treat certain
cases of discogenic or NP mediated back pain, in which
increased levels of proinflammatory cytokines are respon-
sible for pain sensation. The in vitro cell culture results
clearly showed that TPL could effectively inhibit several
proinflammatory cytokines and matrix degrading enzymes,
which are thought to play a major role during symptomatic
disc degeneration. Simultaneously, TPL induced expres-
sion of disc-specific matrix proteins. However, in vivo
experiments will be needed to verify that TPL is an
attractive, new therapeutic agent for degenerative disc
disease by preventing further degradation of the tissue and
exhibiting an analgetic effect due to inhibition of proin-
flammatory cytokines.
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